clinical perspectives on her2-targeted antibody-drug conjugates: treatment-related adverse events
Published 3 months ago • 4 plays • Length 37:44Download video MP4
Download video MP3
Similar videos
-
18:25
emerging antibody-drug conjugates in breast cancer: an expert analysis of promising therapies
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
1:11:01
evolving paradigms of hormone receptor-positive breast cancer: the rise of antibody-drug conjugates
-
2:10
targeting low her2 expression with antibody-drug conjugates
-
28:19
s3 episode 4: the future of antibody-drug conjugates in lung cancer treatment
-
28:57
for pharmacists: evolution of her2-targeted therapy in gastroesophageal adenocarcinoma
-
24:04
evolution of her2-targeted therapy in biliary tract cancer
-
3:34
targeting tumours: challenges of antibody-drug conjugates
-
1:44
what are antibody-drug conjugates and how do they work against cancer?
-
10:21
novel antibody-drug conjugates (adcs) technologies for management of mbc
-
38:09
clinical spotlight: harnessing the power of antibody-drug conjugates in non-small cell lung cancer
-
6:22
what are antibody drug conjugates?
-
57:16
antibody-drug conjugates in the clinic:
-
3:36
her2 breast cancer: evolution of antibody-drug conjugates
-
1:05:01
tackling the practicalities of antibody–drug conjugate therapy for solid tumors
-
1:06
dr. edith perez on the antibody-drug conjugate t-dm1
-
1:38
dr. hart on antibody-drug conjugates in her2 breast cancer
-
28:57
evolution of her2-targeted therapy in gastroesophageal adenocarcinoma
-
1:33
antibody-drug conjugates (adcs) in nsclc